Helios Technologies (HLIO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
4 May, 2026Executive summary
Returned to growth in 2025 with $839M in sales (+4% YoY), gross margin expansion to 32.3%, and record cash from operations of $127M.
Initiated first-ever share repurchase program, repurchasing $13.6M in stock and reducing total debt by $82M.
Completed divestiture of Custom Fluidpower, restructured engineering resources, and focused on core platforms.
Leadership transitions included the appointment of a new President & CEO and CFO, and a new Chair of the Board.
The CORE 2030 Strategy aims for sustainable growth and long-term value creation.
Voting matters and shareholder proposals
Election of three directors for terms expiring in 2029 and one director for a term expiring in 2027.
Ratification of Grant Thornton LLP as independent auditor for fiscal year ending January 2, 2027.
Advisory vote to approve named executive officer compensation (Say on Pay).
Approval of amendment and restatement of the 2023 Equity Incentive Plan to add 1,000,000 shares.
Board of directors and corporate governance
Board consists of seven members with a majority being independent; Chair is a non-management, independent director.
Board diversity in skills, gender, and international experience; five new directors since 2020.
Mandatory retirement at age 75; active board refreshment and succession planning.
Annual board and committee self-evaluations, with enhanced third-party assessment in 2025.
Four standing committees: Audit, Compensation, Governance, and Nominating, all comprised of independent directors.
Latest events from Helios Technologies
- Strong 3Q25 growth and innovation drive a positive 2025 outlook, supported by a diversified portfolio.HLIO
Investor presentation13 Jul 2026 - Q1 2025 sales fell 8% YoY, but cash flow, margins, and debt reduction remained strong.HLIO
Q1 20258 Jul 2026 - Transformation, margin expansion, and operational resilience drive future growth.HLIO
Baird 2024 Global Industrials Conference8 Jul 2026 - Sequential margin and cash flow gains offset year-over-year sales declines.HLIO
Q2 20248 Jul 2026 - Imminent ARDS therapy launch in Japan and global phase III trial signal major growth ahead.HLIO
Jefferies Global Healthcare Conference 202611 Jun 2026 - Q1 2026 sales up 17% with record margins, cash flow, and a raised full-year outlook.HLIO
Q1 202618 May 2026 - Director elections, auditor ratification, and equity plan amendment up for shareholder vote.HLIO
Proxy filing7 May 2026 - Record Q4 and FY25 results, margin gains, and cash flow set up continued growth in FY26.HLIO
Q4 202527 Apr 2026 - Core 2030 targets $1.6B sales, 25%+ EBITDA margin, and accelerated innovation by 2030.HLIO
Investor Day 202620 Mar 2026